A detailed history of China Universal Asset Management Co., Ltd. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 19,537 shares of NTLA stock, worth $295,399. This represents 0.04% of its overall portfolio holdings.

Number of Shares
19,537
Previous 11,333 72.39%
Holding current value
$295,399
Previous $253,000 58.5%
% of portfolio
0.04%
Previous 0.04%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$19.72 - $27.36 $161,782 - $224,461
8,204 Added 72.39%
19,537 $401,000
Q2 2024

Jul 19, 2024

SELL
$20.02 - $27.22 $142,962 - $194,378
-7,141 Reduced 38.65%
11,333 $253,000
Q1 2024

Apr 29, 2024

BUY
$23.82 - $32.8 $193,394 - $266,303
8,119 Added 78.41%
18,474 $508,000
Q4 2023

May 21, 2024

SELL
$23.16 - $32.34 $188,036 - $262,568
-8,119 Reduced 43.95%
10,355 $315,000
Q4 2023

Jan 23, 2024

BUY
$23.16 - $32.34 $187,410 - $261,695
8,092 Added 357.58%
10,355 $316,000
Q3 2023

May 21, 2024

BUY
$31.62 - $45.78 $35,034 - $50,724
1,108 Added 95.93%
2,263 $71,000
Q3 2023

Oct 30, 2023

BUY
$31.62 - $45.78 $35,034 - $50,724
1,108 Added 95.93%
2,263 $72,000
Q2 2023

May 21, 2024

SELL
$34.58 - $46.03 $1,279 - $1,703
-37 Reduced 3.1%
1,155 $47,000
Q2 2023

Jul 27, 2023

SELL
$34.58 - $46.03 $1,279 - $1,703
-37 Reduced 3.1%
1,155 $47,000
Q1 2023

May 21, 2024

BUY
$33.3 - $44.82 $7,925 - $10,667
238 Added 24.95%
1,192 $44,000
Q1 2023

Apr 27, 2023

BUY
$33.3 - $44.82 $7,925 - $10,667
238 Added 24.95%
1,192 $44,000
Q4 2022

May 21, 2024

SELL
$33.21 - $62.69 $581,839 - $1.1 Million
-17,520 Reduced 94.84%
954 $33,000
Q4 2022

Jan 31, 2023

BUY
$33.21 - $62.69 $2,922 - $5,516
88 Added 10.16%
954 $33,000
Q3 2022

Oct 21, 2022

BUY
$53.92 - $71.7 $38,391 - $51,050
712 Added 462.34%
866 $48,000
Q4 2021

Feb 11, 2022

BUY
$100.76 - $138.36 $15,517 - $21,307
154 New
154 $18,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.15B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.